<DOC>
	<DOCNO>NCT00829985</DOCNO>
	<brief_summary>There currently effective way prevent development allergic rhinitis ( nasal allergy ) asthma cure . Sublingual immunotherapy ( SLIT ) , type therapy allergen place tongue , may way control possibly prevent allergic rhinitis asthma . However , detailed research approach limit . The purpose study evaluate safety efficacy sublingual cockroach extract give adult perennial allergic rhinitis , asthma , .</brief_summary>
	<brief_title>Biomarker-based Cockroach Sublingual Immunotherapy Study ( BioCSI )</brief_title>
	<detailed_description>Over last two decade , prevalence asthma dramatically increase many part world . Currently , effective way prevent development nasal allergy asthma , cure disease . Sublingual immunotherapy ( SLIT ) may help reduce symptom allergy asthma . The purpose study evaluate safety efficacy cockroach extract give sublingually adults perennial ( year-round ) nasal allergy , asthma , . At study entry , participant receive dose placebo five incremental dos cockroach extract placebo 15-minute interval observe clinical research staff . Doses continue give sign symptom occur indicate participant difficulty tolerate drug , maximum study dose reach . For next 6 month , participant take maximum study dose cockroach extract placebo daily home . This study consist 8 study visit . Skin test , breathe test , blood collection occur study screen visit study . At study entry , participant teach use EpiPen event severe allergic reaction time study . A physical oral exam , breathe test , blood collection occur study entry follow-up visit .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>History perennial allergic rhinitis , asthma , minimum 1 year prior study entry ; Positive skin prick test German cockroach ; No known contraindication therapy glycerinated German cockroach allergenic extract placebo ; Willing sign write Informed Consent prior initiation study procedure . Can perform spirometry screen ; Have clinically significant abnormal laboratory value ; Have Asthma classification severe persistent screening ; Hospitalized asthma within 6 month prior study entry ; Lifethreatening asthma exacerbation require intubation , mechanical ventilation , result hypoxic seizure within 2 year prior study entry ; No access telephone ; Received allergen immunotherapy within last 12 month prior study entry plan initiate resume immunotherapy study ; Treatment antiimmunoglobulin E ( antiIgE ) therapy within 1 year study entry ; Received investigational drug within 30 day prior study entry plan use investigational drug study ; Experienced nausea , vomit , abdominal pain cramp , diarrhea within 3 month prior study entry ; Refuse sign Epinephrine Autoinjector Training Form ; Does primarily speak English ; Plan move area study period ; History idiopathic anaphylaxis anaphylaxis grade 3 ; Using tricyclic antidepressant betaadrenergic blocker drug ; Clinically unacceptable complete blood count ( CBC ) liver function test , define hemoglobin le 11.5 male 10.0 female , platelet count less 150,000 Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) great twice upper limit normal ; Any condition , opinion investigator , would interfere study ; Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rhinitis , Allergic , Perennial</keyword>
	<keyword>Rhinitis , Allergic , Seasonal</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Asthma</keyword>
	<keyword>Nasal Allergies</keyword>
	<keyword>Hypersensitivity</keyword>
</DOC>